Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

2cureX: IndiTreat market launch imminent

CB

Christian Binder

Redeye returns with an updated take on 2cureX following TICC trial result publication. Following this successful proof-of-concept, the company is now ready for IndiTreat commercialization in metastatic colorectal cancer. Reassessing its commercial outlook and our financial estimates, we have updated our fair value range.

Disclosures and disclaimers